A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

Abstract Background Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in associa...

Full description

Bibliographic Details
Main Authors: Emilie Lereclus, Mira Tout, Alban Girault, Nadine Baroukh, Morgane Caulet, Christophe Borg, Olivier Bouché, David Ternant, Gilles Paintaud, Thierry Lecomte, William Raoul
Format: Article
Language:English
Published: BMC 2017-03-01
Series:BMC Cancer
Subjects:
Bevacizumab
Vascular endothelial growth factor
Th17-related cytokines
IL-17 polymorphisms
Metastatic colorectal cancer
Survival analysis: score
Online Access:http://link.springer.com/article/10.1186/s12885-017-3210-z

Internet

http://link.springer.com/article/10.1186/s12885-017-3210-z

Similar Items